Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma.
Azad SaeiPieter Johan Adam EichhornPublished in: Molecular & cellular oncology (2018)
Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as a negative regulator of mitogen-activated protein kinase (MAPK) pathway by targeting v-raf murine sarcoma viral oncogene homolog B (BRAF) for degradation, a process which is lost in a large proportion of BRAF mutant melanoma patients, resulting in resistance to BRAF inhibitor therapies.
Keyphrases
- wild type
- metastatic colorectal cancer
- end stage renal disease
- transcription factor
- ejection fraction
- newly diagnosed
- chronic kidney disease
- signaling pathway
- sars cov
- prognostic factors
- peritoneal dialysis
- oxidative stress
- binding protein
- small molecule
- skin cancer
- protein protein
- patient reported outcomes
- tyrosine kinase
- protein kinase